JP MORGAN 2015: Enanta CEO on 'exciting' Viekira launch, R&D pipeline
This article was originally published in Scrip
Executive Summary
Both the commercial launch of Enanta Pharmaceuticals's first approved hepatitis C virus (HCV) drug – the paritaprevir component of the twice-daily, four-drug Viekira Pak – and the company's ability to advance additional drugs in the clinic are powered by a more than eight-year-old partnership with AbbVie.